ArticleRheumatic diseases clinics of North America2010
Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.
Article in Rheumatic diseases clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting type I interferon in lupus panniculitis: a case-based systematic literature review.Rheumatology international · 2026Pooled it
- Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2023Trial
- Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.Advances in therapy · 2025Article
- From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists.The Journal of clinical and aesthetic dermatology · 2025Review
- Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.Rheumatology international · 2023Article
- Molecular Characterization of Hepatitis B Virus Infection in a Patient with Cutaneous Lupus Erythematosus.Diagnostics (Basel, Switzerland) · 2022Article
- Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation.Science translational medicine · 2022Article
- Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases.Clinical, cosmetic and investigational dermatology · 2022Review
- Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Rheumatology and therapy · 2020Article
- Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus.Lupus science & medicine · 2020Observational
- Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.JAMA dermatology · 2018Observational
- Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.Postepy dermatologii i alergologii · 2018Article
- Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.Lupus science & medicine · 2016Article
- Cutaneous lupus erythematosus: An update.Indian dermatology online journal · 2014Review
- Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre.The British journal of dermatology · 2013Article
- [Cutaneous lupus erythematosus and skin manifestations in systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2013Article
- Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.Current dermatology reports · 2013Article
- A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus.The British journal of dermatology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This article provides an overview of cutaneous lupus erythematosus, including classification schemes, disease subtypes, and therapy. It also describes the Cutaneous Lupus Erythematosus Disease Area and Severity Index, a novel clinical outcome instrument that quantifies cutaneous activity and damage in cutaneous lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.